Image by Jaap Arriens / NurPhoto via Getty / Futurism
More and more people are turning to weight loss injectables such as Wegovy and Mounjaro. While these medications are gaining credibility when used properly, pharmacy experts are expressing concern that not everyone prescribed these drugs should have access to them.
The United Kingdom’s National Pharmacy Association (NPA) is raising alarms about the potential risks associated with people with histories of disordered eating obtaining these drugs through online channels. In a letter to the UK’s General Pharmaceutical Council, the NPA is advocating for stricter regulations on the online sale of glucagon-like peptide-1 receptor/agonist (GLP-1) drugs.
These medications mimic feelings of fullness and are prescribed not only for weight loss but also to manage type 2 diabetes. The current system often requires only basic online questionnaires for purchase, raising significant concerns.
NPA’s Concerns and Proposed Solutions
The NPA is proposing a requirement for longer, at least 20-minute consultations with a real doctor before dispensing these medications. This approach aims to ensure patients receive proper evaluation and that their medical history is considered.
“We are concerned that the current regulations allow some patients to inappropriately access weight-loss injections without proper consultation or examination of historical medical records,”
stated Nick Kaye, chairman of the NPA in the letter.
Currently, online pharmacies in many countries allow individuals to purchase GLP-1s with minimal steps, raising fears about potential misuse and the risks associated with unregulated drug sales.
Risks Associated with Unrestricted Online Sales
Beyond concerns about dubious online retailers selling unregulated compounded versions of these drugs, there is a fear that people with eating disorders may misrepresent their medical history or overlook significant gastrointestinal side effects.
The NPA believes that while online services can be beneficial, they must include a full consultation to ensure the drugs are supplied to those who need them most, especially those with type 2 diabetes.
Previous Warnings and Clinical Observations
This is not the first time similar warnings have been issued. Aaron Keshen, codirector of the Nova Scotia Provincial Eating Disorder Service in Halifax, Canada, shared his clinical observations.
“We noticed clinically that we were getting more and more people into our clinical services that had been started on GLP-1 agonists and had experienced new onset or worsening eating disorder symptoms,”
Keshen explained.
The specialist emphasized that while some individuals may benefit from moderate weight loss, rapid weight loss due to excessive dietary restriction is never healthy.
Expert Opinion on GLP-1 Drugs
Despite these concerns, it’s important to acknowledge the significant health benefits associated with GLP-1 drugs. For instance, a large study found that Ozempic offers a broad range of health benefits beyond just weight loss.
More on GLP-1s: Huge Study Finds Constellation of Health Benefits for Ozempic Beyond Weight Loss
Conclusion
The debate over the regulation of weight loss injectables highlights the need for a balanced approach that prioritizes patient safety. Stricter guidelines and consultations can help prevent misuse and ensure that these medications are used appropriately.
As the use of GLP-1 drugs continues to grow, addressing these concerns is crucial. Pharmacy experts advocate for a system that combines the convenience of online sales with the necessary clinical oversight to protect patient health.
Your Thoughts: We want to hear from you. What do you think about the proposed regulations on online sales of weight loss injectables? Share your thoughts below!
